KETO-DAROLUTAMIDE

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C19H17ClN6O2
Molecular Weight	396.83
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@@H](CN1C=CC(=N1)C2=CC=C(C#N)C(Cl)=C2)NC(=O)C3=NNC(=C3)C(C)=O

InChI

InChIKey=GMBPVBVTPBWIKC-NSHDSACASA-N

InChI=1S/C19H17ClN6O2/c1-11(22-19(28)18-8-17(12(2)27)23-24-18)10-26-6-5-16(25-26)13-3-4-14(9-21)15(20)7-13/h3-8,11H,10H2,1-2H3,(H,22,28)(H,23,24)/t11-/m0/s1

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26137992

ORM-15341 is an active main metabolite of ODM-201, which is structurally distinct from any known antiandrogens including the second-generation antiandrogens enzalutamide. ORM-15341 is a potent and full antagonist for human androgen receptor. It was shown, that in VCaP prostate cancer cells containing endogenous AR gene amplification and overexpressing AR, ORM-15341 inhibited cell proliferation more efficiently than enzalutamide or ARN-509.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Androgen Receptor 167 Target ID: CHEMBL1871 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26137992	Antagonist 2778		38.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Unknown 2578

PubMed

Title	Date	PubMed
Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies.	2015 Jul 3	26137992

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Unknown

In Vitro Use Guide

HepaRG cells were treated with 10 μM of ORM-15341

Name

Type

Language

KETO-DAROLUTAMIDE

Common Name

English

ORM-15341

Common Name

English

1H-PYRAZOLE-3-CARBOXAMIDE, 5-ACETYL-N-((1S)-2-(3-(3-CHLORO-4-CYANOPHENYL)-1H-PYRAZOL-1-YL)-1-METHYLETHYL)-

Systematic Name

English

Code System Code Type Description

EPA CompTox

DTXSID101111196